DxS Signs a License with DiagnoCure for its Scorpions® Technology
Complete the form below to unlock access to ALL audio articles.
DxS Ltd announced that it has granted a licence to DiagnoCure Inc. from Canada, for DxS’ Scorpions molecular diagnostic technology. Under the terms of the agreement DiagnoCure will gain access to Scorpions for the development of their GCC- based molecular test for colorectal cancer.
Dr Timothy J. Holzer, Vice President of R&D of DiagnoCure said of the agreement “The Scorpions molecular diagnostic technology has the potential to significantly improve productivity and lower cost with regard to the processing of our gene-based tests. Most importantly, we intend to make use of it in our new GC-C tests for colorectal cancer”.
The DiagnoCure test uses Scorpions to detect GC-C (guanylyl cyclase c), a gene that appears normally in cells lining the intestinal tract, but is found on the outside of the intestine when colorectal cancer has metastasized.
DxS’ says that its Scorpions technology is ideally suited for cancer in vitro diagnostics, the probes are highly sensitive, sequence–specific, bi-functional molecules containing a PCR primer covalently linked to a probe. Scorpion probes can provide strong fluorescent signals, equence discrimination, short reaction times, and predictable probe design.
The interaction of the probe and the desired target occurs very and in advance of any competing side reactions such as the formation of internal secondary structures or re-annealing. The intra-molecular nature of the Scorpions reaction means that it is suited for quantitative, real-time PCR analysis.
Financial terms were not disclosed.
